ATE161174T1 - Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung - Google Patents

Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung

Info

Publication number
ATE161174T1
ATE161174T1 AT94911799T AT94911799T ATE161174T1 AT E161174 T1 ATE161174 T1 AT E161174T1 AT 94911799 T AT94911799 T AT 94911799T AT 94911799 T AT94911799 T AT 94911799T AT E161174 T1 ATE161174 T1 AT E161174T1
Authority
AT
Austria
Prior art keywords
solid preparation
production
release solid
high release
active agent
Prior art date
Application number
AT94911799T
Other languages
English (en)
Inventor
Jean Paul Remon
Original Assignee
Univ Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Gent filed Critical Univ Gent
Application granted granted Critical
Publication of ATE161174T1 publication Critical patent/ATE161174T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94911799T 1993-04-22 1994-04-21 Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung ATE161174T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BE9300407A BE1006990A5 (nl) 1993-04-22 1993-04-22 Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.

Publications (1)

Publication Number Publication Date
ATE161174T1 true ATE161174T1 (de) 1998-01-15

Family

ID=3886999

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94911799T ATE161174T1 (de) 1993-04-22 1994-04-21 Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung

Country Status (12)

Country Link
US (1) US6368634B1 (de)
EP (1) EP0695172B1 (de)
JP (1) JP2960169B2 (de)
AT (1) ATE161174T1 (de)
AU (1) AU6421594A (de)
BE (1) BE1006990A5 (de)
CA (1) CA2161016A1 (de)
DE (1) DE69407404T2 (de)
DK (1) DK0695172T3 (de)
ES (1) ES2113095T3 (de)
GR (1) GR3026338T3 (de)
WO (1) WO1994023700A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
DE4318577A1 (de) * 1993-06-04 1994-12-08 Merck Patent Gmbh Schmiermittelfreie, arzneimittelhaltige Tabletten
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
CA2159419C (en) * 1994-10-17 2006-07-04 Pieter De Haan Solid pharmaceutical composition comprising an excipient capable of binding water
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
TWI225402B (en) * 1996-03-13 2004-12-21 Biochemie Gmbh Auxiliary-free agglomerates
MX9801835A (es) 1996-07-08 1998-08-30 Mendell Co Inc Edward Matriz de liberacion sostenida para medicamentos insolubles de dosis altas.
WO1999017743A1 (en) * 1997-10-07 1999-04-15 Fuisz Technologies Ltd. Dosage forms having improved release properties
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
CA2348452A1 (en) * 1998-10-27 2000-05-04 Biovail Technologies Ltd. Microparticles containing peg and/or peg glyceryl esters
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
WO2001078725A2 (en) * 2000-04-13 2001-10-25 Synthon B.V. Modified release formulations containing a hypnotic agent
SE0200154D0 (sv) * 2002-01-21 2002-01-21 Galenica Ab New process
WO2003072085A1 (fr) * 2002-02-27 2003-09-04 Shionogi & Co., Ltd. Preparations solides contenant un medicament a peine soluble dans l'eau d'une meilleure absorbabilite
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
CA2718416C (en) * 2008-03-13 2018-01-02 Mallinckrodt Inc. Multi-function, foot-activated controller for imaging system
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US11559530B2 (en) 2016-11-28 2023-01-24 Lipocine Inc. Oral testosterone undecanoate therapy
WO2020018974A1 (en) 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
EP3991750A4 (de) 2019-06-26 2022-08-03 Ricoh Company, Ltd. Pharmazeutische zusammensetzung
US20220023216A1 (en) 2019-06-26 2022-01-27 Ricoh Company, Ltd. Instantly soluble particle and method for producing the same

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146167A (en) * 1961-10-05 1964-08-25 Smith Kline French Lab Method of preparing sustained release pellets and products thereof
GB1148802A (en) * 1965-06-18 1969-04-16 Eastman Kodak Co Microcrystalline cellulose granules containing useful oils
CH523017A (de) * 1969-11-21 1972-05-31 Agripat Sa Schädlingsbekämpfungsmittel
US3655864A (en) * 1970-09-21 1972-04-11 Smith Kline French Lab Glyceryl tristerate and higher fatty acid mixture for improving digestive absorption
GB1367608A (en) * 1973-03-09 1974-09-18 Biolog Concepts Inc Oral pharmaceutical dosage form
USRE33963E (en) * 1981-10-29 1992-06-16 Bayer Aktiengesellschaft Solid rapidly released medicament preparations containing dihydropyridines, and processes for their preparation
FR2581541B1 (fr) * 1985-05-09 1988-05-20 Rhone Poulenc Sante Nouvelles compositions pharmaceutiques permettant la liberation prolongee d'un principe actif et leur procede de preparation
LU86099A1 (fr) * 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
DD249186A1 (de) * 1986-05-26 1987-09-02 Univ Halle Wittenberg Herstellungsverfahren einer neuen glibenclamid-arzneiform mit hoher bioverfuegbarkeit
EP0272336B1 (de) * 1986-12-18 1991-10-23 Kurt H. Prof. Dr. Bauer Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
EP0418596A3 (en) 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
SE9003296L (sv) * 1990-10-16 1992-04-17 Kabi Pharmacia Ab Foerfarande foer att formulera laekemedel
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
JPH0597672A (ja) * 1991-10-08 1993-04-20 Terumo Corp アミド誘導体含有固形製剤およびその製造方法

Also Published As

Publication number Publication date
JP2960169B2 (ja) 1999-10-06
ES2113095T3 (es) 1998-04-16
GR3026338T3 (en) 1998-06-30
EP0695172A1 (de) 1996-02-07
US6368634B1 (en) 2002-04-09
EP0695172B1 (de) 1997-12-17
WO1994023700A1 (en) 1994-10-27
DE69407404T2 (de) 1998-07-02
AU6421594A (en) 1994-11-08
BE1006990A5 (nl) 1995-02-07
JPH09500093A (ja) 1997-01-07
DK0695172T3 (da) 1998-08-24
DE69407404D1 (de) 1998-01-29
CA2161016A1 (en) 1994-10-27

Similar Documents

Publication Publication Date Title
ATE161174T1 (de) Feste zubereitung mit hoher freisetzung, ihre herstellung und verwendung
ATE102044T1 (de) Stabilisiertes fgf-mittel und dessen herstellung.
MY129941A (en) Novel dihydro-isoquinoline derivatives
AU2840789A (en) Continuous release pharmaceutical compositions
IL117532A0 (en) Production of compositions in the form of a solid solution of an active substance in a polymer matrix
AU8142594A (en) Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
ES2138584T3 (es) Sistema de suministro de farmacos que implica la reaccion entre una proteina o un polipeptido y un polimero biodegradable hidrofobo.
DK74187A (da) Praeparat til langsom frigivelse samt fremgangsmaade til fremstilling deraf
ITRM920590A0 (it) Sistema per la realizzazione distrutture in fibra di carbonio, e procedimento per detto, particolarmente idoneo per applicazioni aeronautiche.
UY24210A1 (es) Composicion de gel o de barra antitranspirante libre de pegajosidad, clara o translucida y metodo de fabricacion
ATE221773T1 (de) Formulierungen mit gesteuerter freisetzung
DE69427908D1 (de) Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
IS1620B (is) Aðferð til framleiðslu á lyfjablöndum sem innihalda nifedipine
ES2130638T3 (es) Sistema para la liberacion de sustancia activa, filmogeno, vaporizable, para utilizar en las plantas.
GR3030732T3 (en) Pharmaceutical compositions including a drug, a cross-linked polymeric substance, an oil, and a surface active agent.
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
DE69431162D1 (en) Fenbendazolformulierungen
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
ATE169452T1 (de) Feste planzenschutzmittel-formulierung
ES8601756A1 (es) Metodo de fabricar una estructura compuesta coherente.
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
ATE147742T1 (de) 8-alpha-acylamino-ergoline, ihre herstellung und verwendung als arzneimittel
ATE262596T1 (de) Pulverförmige dextrose und verfahren zur herstellung derselben
Pincus et al. Norflox or Norflex?
ES2101531T3 (es) Derivados de benzo(f)quinoxalinadiona, su preparacion y su utilizacion en medicamentos.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee